Get notified when LABT files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Going Concern (new) — The company explicitly states substantial doubt about its ability to continue as a going concern within one year.
Lakewood-Amedex Biotherapeutics files 424B3 after $7.5M Series C; net proceeds $6.8M, GAAP net loss $4.7M
Filed August 17, 2026 · ~1 min read
Key Changes
-
high
The company raised $7.5M gross ($6.8M net) via Series C preferred stock in Q2 2026.
Risk Factors verify on EDGAR → -
high
GAAP net loss was $4.7M for the six months ended June 30, 2026, up from $1.2M a year earlier.
Risk Factors verify on EDGAR → -
high
Management expects current cash to fund operations only into Q1 2027.
Risk Factors verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (MU 10-K) is open in full — no account needed.
Partner
Trade LABT commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 1, 2026 · How we verify